Can a new class of generic and new pharmaceutical drugs be imported by Russia, India, China and South Africa from Brazil? The answer is yes. The FDA and DEA are behind by at least 2 to 5 years, depending be it technology or legal structure, when it comes to the development of new generic drugs and new pharmaceutical drugs based on cannabinoid molecules.
The door way to spectacular growth opportunities is not waiting for the FDA and DEA because the rest of the world involved with cannabinoid based drugs has moved years ahead of them.
As investors we need to realize and appreciate the global opportunities in today's day and age and shed ourselves of the illusion that the U.S. is the center of the 'universe' because they no longer are and that has shown itself not only in the development of new cannabinoid pharmaceutical applications but like I wrote several days back, India with their robotic rover on the Moon and China with their space station. Pharmaceutical cannabinoids are just another example.
This is why I said, forget about the DEA, Pidduck stated loud and clear, it will be the Brazil business that will drive them into profits in Q1 2024 and that when encompassing the economic developing bloc of BRICS countries is just the tip of the iceberg.
And Pidduck also stated loud and clear, when ANVISA of Brazil approves that drug with their pharma partner in Brazil they will release more news and information.
When that happens, LABS will be the most profitable and fastest growing cannabis related company in all of North America including rest of world.